ALKS - Alkermes plc
Chart Events
Triple Moving Average Crossover
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 29.32 |
| Open | 29.11 |
| Bid | 28.74 x 800 |
| Ask | 28.80 x 900 |
| Day's Range | 28.56 - 29.20 |
| 52 Week Range | 21.75 - 32.23 |
| Volume | |
| Avg. Volume | 1,235,259 |
| Market Cap | 4.811B |
| Beta (5Y Monthly) | 0.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.00 |
| Earnings Date | Apr 26, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 35.33 |
Fair Value
Related Research
Investor's Business DailyThe Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
ZacksAlkermes (ALKS) Up 3.7% Since Last Earnings Report: Can It Continue?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PR NewswireAlkermes Files Definitive Proxy Statement and Issues Letter to Shareholders Detailing Business Execution That Has Driven Strong Performance and Delivered Shareholder Value
Alkermes plc (Nasdaq: ALKS) (the Company) today filed its definitive proxy statement with the U.S. Securities and Exchange Commission (SEC) and issued a letter to its shareholders in connection with the Company's upcoming 2023 Annual General Meeting of Shareholders (the Annual Meeting), which is scheduled to be held on June 29, 2023. The letter details the Company's successful execution and value creation since the announcement of its Value Enhancement Plan in December 2020. The Value Enhancemen
PR NewswireAlkermes Highlights Data From Psychiatry Portfolio at Spring 2023 Scientific Conferences
Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry portfolio—which includes LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil)—at four scientific conferences this spring. Several of these meetings coincide with Mental Health Awareness Month in May, an important moment in the year that provides an opportunity to raise awareness about mental health conditions, support the millions of people living with these complex diseases,
- PR Newswire
Alkermes Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Alkermes plc (Nasdaq: ALKS) today announced the acceptance of two abstracts related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy, for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago June 2-6, 2023. Trial-in-progress posters from the actively recruiting phase 2 ARTISTRY-6 clinical trial and phase 3 ARTISTRY-7 clinical trial will be presented. ARTISTRY-6 is eva
- PR Newswire
Alkermes Files Preliminary Proxy Statement and Provides Update on Annual Director Nomination Process
Alkermes plc (Nasdaq: ALKS) today filed its preliminary proxy statement with the U.S. Securities and Exchange Commission (SEC) in connection with its upcoming Annual General Meeting of Shareholders (the Annual Meeting). The company also provided an update on its annual director nomination process and its ongoing shareholder engagement efforts. The preliminary proxy statement is available on the Investor Relations section of the company's website at www.alkermes.com.
ACCESSWIREAlkermes Named Among Top 100 Companies Leading in Wellbeing by Ibec
NORTHAMPTON, MA / ACCESSWIRE / May 8, 2023 / Alkermes Alkermes is proud to be selected as a 2023 Top 100 Companies Leading in Wellbeing by Ibec! This recognition acknowledges companies in Ireland who are leading the way in supporting employee wellbeing. ...
Simply Wall St.Insufficient Growth At Alkermes plc (NASDAQ:ALKS) Hampers Share Price
With a price-to-sales (or "P/S") ratio of 4.4x Alkermes plc ( NASDAQ:ALKS ) may be sending very bullish signals at the...
ACCESSWIREAlkermes Athlone Shortlisted for Gradirleand’s 17th Annual Graduate Recruitment Awards
Alkermes' Athlone site was recently shortlisted for gradireland's 17th annual Graduate Recruitment Awards! This award recognizes outstanding graduate intake programs across Ireland.
ACCESSWIREAlkermes Athlone Receives Award at Ireland’s 2023 Health & Safety Excellence Awards
Alkermes Athlone site recently received a 2023 award in the Life Sciences category at Ireland's 2023 Health & Safety Excellence Awards. This recognition is a testament to our employees' focus on building a culture of safety and risk management in Athlone.
ACCESSWIREAlkermes Inspiration Grants Now Open for Applications
The 2023 Alkermes Inspiration Grants® program is now open for applications! These grants are designed to support programs or organizations for people affected by serious mental illness, addiction and cancer.
ZacksAlkermes (ALKS) Q1 Earnings & Revenues Beat Estimates
Alkermes (ALKS) reports encouraging first-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi and Vivitrol.
- ACCESSWIRE
Clinical Trials Integral to Providing More Treatment Options for Platinum-Resistant Ovarian Cancer (PROC)
Patients diagnosed with platinum-resistant Ovarian Cancer (PROC) often face poor prognosis due to the limited treatment options.
ZacksAlkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
ZacksAlkermes (ALKS) Surpasses Q1 Earnings and Revenue Estimates
Alkermes (ALKS) delivered earnings and revenue surprises of 133.33% and 1.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Alkermes plc Reports First Quarter 2023 Financial Results
Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2023.
- PR Newswire
Alkermes Announces Second Interim Award in Janssen Pharmaceutica Arbitration
Alkermes plc (Nasdaq: ALKS) today announced that on April 19, 2023 it received a second interim award (the "Second Interim Award") from the arbitral tribunal (the "Tribunal") in its arbitration proceedings in respect of two license agreements with Janssen Pharmaceutica N.V. ("Janssen"), a subsidiary of Johnson & Johnson.
ACCESSWIREAlkermes' Katie Joyce To Speak at Women in Bio 2023
Last week, Katie Joyce, VP of Corporate Affairs, participated in a panel discussion at this year's Women in Bio (WIB) Management Track event featuring women leaders in life science. This year's event gave attendees the opportunity to connect with industry leaders and hear from a panel of executive women leaders discussing their career paths and individual experiences.
ACCESSWIREAlkermes Announces Application Period for 2023 Alkermes Inspiration Grants® Program To Support Innovative Initiatives Focused on People Affected by Addiction, Serious Mental Illness or Cancer
Alkermes plc (Nasdaq:ALKS) recently announced that the company will accept applications for its Alkermes Inspiration Grants® program beginning on May 1, 2023.
- ACCESSWIRE
Alcohol Use Disorder Doesn’t Discriminate
NORTHAMPTON, MA / ACCESSWIRE / April 20, 2023 / Alkermes Alcohol Use Disorder (AUD) does not discriminate. But some communities are disproportionately affected. As we recognize both National Minority Health Month and Alcohol Awareness Month, we ...
- PR Newswire
Alkermes to Report First Quarter Financial Results on April 26, 2023
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, April 26, 2023 to discuss the company's first quarter financial results.
- Simply Wall St.
Breakeven On The Horizon For Alkermes plc (NASDAQ:ALKS)
With the business potentially at an important milestone, we thought we'd take a closer look at Alkermes plc's...
- PR Newswire
Alkermes Announces Submission of Confidential Draft Form 10 Registration Statement for Planned Separation of Oncology Business
Alkermes plc (Nasdaq: ALKS) today announced that it has submitted a confidential draft Form 10 registration statement to the United States Securities and Exchange Commission in connection with the previously announced planned separation of the company's oncology business into an independent, publicly-traded company (Oncology Co.). The company continues to expect to complete the separation in the second half of 2023.
ACCESSWIREAlkermes Recommits to Equality on Equal Pay Day 2023
NORTHAMPTON, MA / ACCESSWIRE / April 12, 2023 / Alkermes (NASDAQ:ALKS) As part of last month's observance of Equal Pay Day , Alkermes reaffirms our commitment to closing long-standing pay gaps between men and women. We are proud of our efforts to ...
- Simply Wall St.
Alkermes (NASDAQ:ALKS) delivers shareholders favorable 26% CAGR over 3 years, surging 8.0% in the last week alone
By buying an index fund, investors can approximate the average market return. But if you buy good businesses at...